Development of cell-free protein synthesis platforms for discovery and/or production of biologicals
Ente erogante: Commissione Europea - Horizon Europe
Scadenza
13 aprile 2027
361 giorni rimanenti
Forma
Non specificata
Budget totale
Non specificato
Contributo max
Non specificato
Descrizione del bando
Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Maintaining an innovative, sustainable, and competitive EU health industry”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:Biopharmaceutical industries get access to streamlined development and production processes for peptide- or protein-based biologicals.Health systems benefit from the availability of enhanced or decentralised production systems for innovative health technologies that involve peptides or proteins, and which improve health and care.Citizens and patients will benefit from better access, availability and affordability of pharmaceuticals based on biologicals. Scope:Cell-Free Protein Synthesis (CFPS) has been employed in fundamental biological research for decades, however, interest for the approach as a viable means for drug development and production has only emerged in recent years. The advantages that CFPS provides in terms of efficiency, simplicity, flexibility, cost- and time savings outweigh the hurdles that are still to be overcome for CFPS to become a routine manufacturing system for peptide- or protein-based biologicals.Currently, there are several CFPS systems used that are either based on prokaryotic or eukaryotic cell lysates (including mammalian) or fully synthetic systems consisting of all the molecular machinery necessary to create functional proteins. The choice of a specific lysate is dictated by the target protein and the end-use application. Proteins that require post-translational modification are generally produced using lysates of mammalian cells. Hence systems based on mammalian cells are of particular interest as they combine properties inherent to eukaryotic cells and their ability to produce human-like glycosylated proteins with the advantages of cell-free synthesis. T
Non capisci questo bando?
L'AI di Bandiora te lo spiega in modo semplice: requisiti, importi, scadenze e a chi è rivolto, tutto chiaro.
Registrati e fatti spiegare il bando dall'AIArea geografica
Tematiche
Requisiti dettagliati
Questo bando è rivolto a - tipologie di impresa in 3 settori ATECO nell'area eu.
Scopri con l'AI se questo bando è adatto alla tua azienda
Analisi automatica di compatibilità, requisiti e matching in tempo reale
Prova gratis 7 giorniQuesto bando fa per la tua azienda?
L'AI di Bandiora analizza la compatibilità con la tua azienda in tempo reale e ti assiste nella compilazione della candidatura, passo dopo passo.
Altri bandi che potrebbero interessarti
Support to test EIC innovations for public and private procurers
Commissione Europea
Scadenza: 17 aprile 2026
Accelerating the discovery and development of chemicals and innovative advanced materials through digitalisation and artificial intelligence (IA) (Innovative Advanced Materials for the EU partnership)
Commissione Europea - Horizon Europe
Scadenza: 21 aprile 2026
Improving availability of secondary raw materials through recycling (IA)
Commissione Europea - Horizon Europe
Scadenza: 21 aprile 2026
Monitoring of secondary raw materials (CSA)
Commissione Europea - Horizon Europe
Scadenza: 21 aprile 2026